December 29, 2015 7:10am

RegMed’s pre-open, along with flagging sector breadth; the lack of buying by traders is an important “tell” that the probability of investing has diminished.

For past momentum stock movers, the reward-to-risk ratio favors a heavy cash position.

Henry’s “7” Tuesday’s indications.

 

The New Year is coming, subscribe or take your losses without complaining!

 

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

 

DOW futures and NASDAQ futures are UP +0.4%

 

U.S. stock futures on Tuesday point to a higher open, as oil rallies and the S&P 500 and Dow look to end a two-day retreat.

European stock markets rose for the first time in three sessions in light holiday trade, trimming sharp losses for the month. The Stoxx Europe 600 index SXXP, +0.77% rallied 1% to 368.13, after losing 0.5% on Monday.

Asian equities closed higher on the second day of 2015's final week, after the Japanese and South Korean markets erased morning losses and the Chinese market eventually closed higher, following a volatile trading session.

Data docket: The S&P/Case-Shiller home prices released at 9:00 a.m. ET, while consumer confidence is scheduled for release at 10:00 a.m.

 

 

The RegMed sector closed NEGATIVE on Monday, with Christmas on Friday following Thursday’s NEGATIVE close after a POSITIVE close on Wednesday, a NEGATIVE close last Tuesday.

 

Another short week:

·         Monday closed NEGATIVE with 29 decliners, 13 advancers and 1 flat;

·         Friday was closed  for Christmas;

·         Thursday closed NEGATIVE <also early close> with 27 decliners, 15 advancers and 1 flat;

·         Wednesday closed POSITIVE with 9 decliners, 32 advancers and 2 flats;

·         Last Tuesday closed NEGATIVE close with 29 decliners, 13 advancers and 1 flat;

 

 

You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you … what are today’s … trades?

  • Stem, cell and gene therapy RegMed (SCGT&RM) stocks closed lower on Monday as I had stated Thursday left us with an ability to realize appreciation from a few oversold positions  or take further losses to start fresh in the New Year.

Following through on what I had said on Monday - one issue that stands out from the pack –ATM usage will limit appreciation!

  • It is a sign of sector “participants” admission of a higher-risk undertaking;

While this is not necessarily a drop-dead indicator of stifled appreciation ahead, it is another sign of a need for cash infusion in the short and near-term - that should be considered warily.

 

 

Tuesday’s indications:

  • Aduro Biotech (ADRO) closed UP +$0.45 to $28.17. Speculators will “nibble “on the edges of appreciation – SELL;
  • Applied Genetic Technologies (AGTC) closed UP +$0.80 to $21.14. Speculators will more than probably take some of the recent profit– SELL;
  • Bellicum Pharma (BLCM) closed DOWN -$1.10 to $19.79. Any “iffy” moves without substance are suspect. Let the share price settle down until the New Year– HOLD;
  • Capricor (CAPR) closed DOWN -$0.12 to $2.97. I haven’t been wrong as CAPR has been a consistent loser even when they have been in play with small volume! The CEO has the tendency to NOT listen to anyone especially the BOD; maybe it’s time for a change! Might this downward movement expose a failed offering?  SELL;
  • Cellectis S.A> (CLLS) closed DOWN -$0.95 to $30.00. CLLS submitted a clinical trial application (CTA) to the Medicines & Healthcare products Regulatory Agency (MHRA) requesting approval to initiate UCART19 First-in-Human clinical investigation in leukemia in the UK.  This study aims to include CD19-positive Acute Lymphoblastic Leukemia (ALL) patients – BUY;
  • Juno Therapeutics (JUNO) closed DOWN -$1.21 to $43.67. Oversold and up +$0.67 or +1.53% in the aftermarket – BUY;
  • MiMedx (MDXG) closed UP +$0.21 to $9.61. Speculators will “nibble” the edges of appreciation – SELL;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.